ArticleJournal of microscopy and ultrastructure
The Utility of SMAD4 and S100P as Diagnostic Immunohistochemical Markers for Pancreatic Ductal Adenocarcinomas in Egyptian Patients.
Article in Journal of microscopy and ultrastructure. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- <p>Unveiling sex differences in pancreatic ductal adenocarcinoma: Current evidence and future directions (Review)</p>.International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is the seventh cause of death caused by the cancer worldwide. It mostly presents at advanced stage. Aim of the Study: To analyze immunohistochemical expressions of SMAD4 and S100P in PDACs as well as correlation between their expressions and other clinical and pathological features. Materials and Methods: Sixty cases of Egyptian patients proved to be PDAC, 19 cases of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) biopsies, and 41 cases of resection specimens, were collected. Results: S100P positive was expressed in 90% of studied cases. Most cases showed focal and strong-to-moderate nuclear expression for S100P. A statistically significant correlation between S100P expression and tumor grade was established in studied cases ( Conclusion: Our data suggest the role of S100P and SMAD4 in pancreatic carcinogenesis. SMAD4 could be used as the diagnostic biomarker for pancreatic adenocarcinomas. There is combined classification accuracy of 98.9%, suggesting that they are a sensitive and specific approach for adenocarcinomas in limited material of EUS-FNAs and that combined panel approach was significantly more accurate than any other individual approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.